**20XX Annual Report**

**IND**

**[PROTOCOL TITLE]**

**Serial [000X]**

**[DATE]**

**Confidential**

Table of Contents

[1 Study information 3](#_Toc360442025)

[1.1 Enrollment Update 3](#_Toc360442026)

[1.2 Brief Description of Study Results 4](#_Toc360442027)

[2 Summary Information 4](#_Toc360442028)

[2.1 Adverse Events: Frequent and Serious 4](#_Toc360442029)

[2.2 Summary of IND Safety Reports 5](#_Toc360442030)

[2.3 Study Subject Deaths 6](#_Toc360442031)

[2.4 Study Subject Dropouts Resulting from Adverse Drug Experiences 6](#_Toc360442032)

[2.5 Understanding of the Drug’s Action 6](#_Toc360442033)

[2.6 List of Preclinical Studies 6](#_Toc360442034)

[2.7 Summary of Manufacturing or Microbiological Changes 6](#_Toc360442035)

[3 General investigational plan 6](#_Toc360442036)

[3.1 Brief Description of the Overall Investigational Plan 6](#_Toc360442037)

[3.1.1 Rationale 6](#_Toc360442038)

[3.1.2 Indication(s) to be Studied 6](#_Toc360442039)

[Primary Study Endpoints 6](#_Toc360442040)

[Secondary Study Endpoints 6](#_Toc360442041)

[3.1.3 Planned Clinical Trials 6](#_Toc360442042)

[3.1.4 Estimated Number of Subjects 6](#_Toc360442043)

[3.1.5 Anticipated Risks 7](#_Toc360442044)

[4 Protocol Modifications 7](#_Toc360442045)

[5 Foreign Marketing Developments 7](#_Toc360442046)

[6 Outstanding business with respect to IND 7](#_Toc360442047)

# Study information

**Title of Study:**

**Study Design:**

**Purpose:**

**Patient Population:**

**Study Status:**

## Enrollment Update

Total enrollment goal:

Total currently enrolled:

[Are there external sites? What are those enrollment numbers?]

**Table 1.2-1 Subject Enrollment by Site**

|  |  |  |  |
| --- | --- | --- | --- |
| **Site** | **Total Enrolled** | **First Enrollment Date** | **Last Enrollment Date** |
| Mt. Sinai |  |  |  |
| **Total US sites** |  |  |  |
| **Total non-US sites** |  |  |  |
| **Total subjects** |  |  |  |

**Table 1.2-2 Subject Demographics**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Female** | **Male** | **Both Genders** |
| **Ethnic Category**  | **N** | **%** | **N** | **%** | **Total** | **%** |
| Hispanic or Latino  |  |  |  |  |  |  |
| Not Hispanic or Latino  |  |  |  |  |  |  |
| **Total** |  |  |  |  |  | 100% |
| **Racial Category (single category per participant)**  | **N** | **%** | **N** | **%** | **Total** | **%** |
| White  |  |  | - | - | - | - |
| Black or African American  | - | - | - | - | - | - |
| Multiracial | - | - | - | - | - | - |
| Other  | - | - | - | - | - | - |
| **Total**  |  | **%** | **-** | **-** | **-** | - |
| **Age at Enrollment Category**  | **N** | **%** | **N** | **%** | **Total** | **%** |
| 18 − 21 years  |  |  |  |  |  |  |
| 22 − 29 years  |  |  |  |  |  |  |
| 30 − 39 years  |  |  |  |  |  |  |
| 40 − 49 years  |  |  |  |  |  |  |
| 50 − 59 years  |  |  |  |  |  |  |
| 60 years and older |  |  |  |  |  |  |
| **Total**  |  |  |  |  |  | 100% |

**Table 1.2-3 Status of Enrolled Participants**

|  |  |
| --- | --- |
| Total Enrollment  |  |
| Total Completed Treatment  |  |
| On Study |  |
|  On treatment  |  |
|  Completed treatment  |  |
|  Off treatment early  |  |
| Terminated Study Early  |  |
|  Completed treatment  |  |
|  Off treatment early  |  |
| Completed Protocol Follow−up  |  |
|  Completed treatment  |  |
|  Off treatment early  |  |
| Termination associated with an adverse experience  |  |

## Brief Description of Study Results

# Summary Information

## Adverse Events: Frequent and Serious

**N=**

|  |  |  |
| --- | --- | --- |
| **Event** | **Grade (n)** | **Total** |
| **1-2** | **3** | **4** | **5** |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

## Summary of IND Safety Reports

A summary list of all IND safety reports submitted during the past year is as follows:

|  |
| --- |
| Protocol:PI: |
| **Report#** | **Report (initial, f/u)** | **Event** | **ReportDate** | **Relationship to study drug** |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

## Study Subject Deaths

## Study Subject Dropouts Resulting from Adverse Drug Experiences

## Understanding of the Drug’s Action

## List of Preclinical Studies

## Summary of Manufacturing or Microbiological Changes

#

# General investigational plan

## Brief Description of the Overall Investigational Plan

### Rationale

### Indication(s) to be Studied

## Primary Study Endpoints

## Secondary Study Endpoints

### Planned Clinical Trials

### Estimated Number of Subjects

### Anticipated Risks

# Protocol Modifications

Changes that were made to the protocol during past year that were reported to FDA and approved by IRB, and changes not yet reported.

# Foreign Marketing Developments

# Outstanding business with respect to IND